The deal marks the tech company's sixth acquisition since January 2017.
Software and data analytics provider RealPage has lined up another acquisition. This time, the firm has an agreement
acquire ClickPay, a comprehensive electronic payment platform servicing 2.3 million units across the multifamily,
homeowners association (HOA), condominium, and co-op segments of real estate, for $218 million.
Coronaviruses must enter host cells to replicate. Cell entry by the virus is mediated by proteases
found in the host. S-001 is an inhibitor of these proteases and prevents the virus from binding to
receptors needed for entry into the host cell. In addition to activity against coronaviruses,
S-001 has shown activity against filoviruses such as Ebola, and the parasite T. cruzi, which is
responsible for the development of Chagas disease.
IDBiologics was founded in 2017 to discover and develop human monoclonal antibodies for the prevention, treatment, and cure of infectious diseases.
Our innovative fully human monoclonal antibody platform enables rapid discovery and optimization of broad and potent therapeutic molecules.
Using this proprietary platform, IDBiologics has accumulated unparalleled breadth in
isolating antibodies for infectious diseases,
with lead candidate molecules to diverse targets moving forward in development.
POPS! Diabetes Care—a revolutionary diabetes care management company—is excited to announce that it has closed an
oversubscribed Series A funding round of $6 million USD due to strong investor demand.
According to a Form D published on April 20, Orchid has raised roughly $36.1 million out of a planned $125.59 million.
Per the Form D filing, 42 investors have taken part in the sale of SAFTs – or Simple Agreements for Future Tokens – thus
far. The SAFT gives accredited investors the right to claim blockchain tokens at a later date, and the investors
involved must meet certain SEC-mandated income or asset thresholds in order to participate.
Have you ever stopped to think about the limitations of technology? Are there any limitations?
As new developments pop up almost every single day, it seems the answer is “no.” And the youth of today are demanding more -
more convenience, more adaptability, and more ease of use. And with the advances in technology,
you can no longer ignore artificial intelligence’s role in making those advances possible.
In fact, AI has a role in all aspects of life from the home to shopping to the workplace.
I recently had the pleasure of speaking to Peter Voss, CEO and chief scientist behind Aigo,
and he explained how artificial intelligence is poised to make our lives a lot more convenient.
Highmark Health is reimbursing Moving Analytics' virtual cardiac rehab tool through an
innovation program and is expected to roll it out more broadly should the tool
lower readmissions and lower costs.
NEW YORK and PARIS, Jan. 23, 2019 /PRNewswire/ -- Templum Markets, LLC,
a registered primary issuance and secondary trading platform for smart securities, and IPwe, Inc.,
the world's first global patent transaction platform,
announce the launch of their patent finance market for Fortune Global 500 and small to medium sized enterprises (SMEs).
Together, Templum Markets and IPwe are creating an entirely new financing framework,
enabling companies to efficiently finance their patented intellectual property,
turning the hundreds of billions of dollars invested in obtaining and maintaining patents into a financeable asset class.
People around the world come up with new ideas and start developing cutting-edge technologies,
devices and code in their backyards. Kira Blackwell, NASA iTech program executive for the agency’s
Space Technology Mission Directorate, emphasized this Oct. 7 as she welcomed entrepreneurs,
judges and intrigued guests to the latest NASA iTech forum in Las Cruces, New Mexico.
Famacash, a mobile marketplace for retailers and a digital wallet for consumers,
has raised $1 million of a $10 million funding round, according to the company’s founder.
CEO and founder of Famacash, Saiful Khandaker, said half a million of the investment came from an angel investor in Kansas and the remaining funds came from a private venture capital firm in New York. The company’s headquarters is based in Alpharetta.
With Famacash, retailers will be able to send consumers deals, coupons and even sell gift cards, Khandaker said. Like Venmo, the app will also provide peer-to-peer money exchanges locally and internationally. Users will be able to withdraw cash from participating bank partners or pay merchants with the Famacash wallet, he said.
Khandaker hopes to offer the Famacash app in the Apple and Google app stores within the next two weeks following a soft launch, with an expansion across the world later on.
Klickly’s proprietary technology is the first and only platform that lets people purchase (with one touch) directly within ads, emails, and social media. The Los Angeles based company’s “smart,” impulse payments protocol enables purchases directly within digital interfaces.
In short, Klickly has implemented a smart, impulse-payments solution for in-advertising experiences. Premier publishers, brands, agencies, and influencers use Klickly’s buy button technology to hyper-charge and commerce-enable their marketing messages.
The world’s first and only “smart” AI-powered button that lets people complete entire purchases (and other CTAs) directly within ads, emails, social media, and websites, Klickly functions equally well on mobile or desktop without ever leaving the page.
n a preclinical model, GSK scientists report a greater immune response to GSK Shingles vaccine (Hz/su) formulations that contain QS-21.
In addition to SAPONEX and TQL-1055, Adjuvance is able to produce a variety of novel QS-21 saponin adjuvants for research and development efforts. Our synthetic processes provides vaccine developers with adaptability through rationally designed structural variants of QS-21. Using our proprietary chemistry, Adjuvance is able to delete and append portions of saponin adjuvants in a manner that provides a diverse array of unique TiterQuil adjuvants.